Provizanto de iVIGA Tap Factory
Kuirejo Kaj Banĉambro Industrio Ĉefa Amaskomunikilaro Kuirejo Kaj Banĉambro Informo
Israeli digital health startup OutSense was awarded a number of key innovation patents for IoT technology, foreign media reported on June 23. The technology gains life-saving medical insights by analyzing human excrement. La firmao arkivis serion de tri patentoj kovrantaj elementojn de sia medicina neceseja sensilo.
The first OutSense patent is for the detection of blood hidden in the toilet bowl. This OutSense device uses reflected light from the toilet bowl to determine the optical signature of hidden blood in feces. Patents for this technology have been granted in the United States, Eŭropo, Japanio kaj Ĉinio. A second patent has been granted in Europe and applications are pending for this patent in other countries. It allows effective analysis of the spatial distribution of the many components of stool and traces of blood. Based on this analysis, La teknologio de OutSense povas identigi la fonton de sango laŭ la gastrointestina vojo. A third patent is pending for the technology, which detects urine dehydration components by analyzing urine and feces.
Laŭ OutSense CEO Yfat Scialom, he predicts that “kun la eksplodo de cifereca medicino. This kind of monitoring will become the norm.” OutSense says the technology, which has already been approved and is pending approval, will provide broad protection for a person’s health by non-invasively extracting hidden blood from feces and urine. Hidden blood is critical for detecting colorectal cancer, inflama intestmalsano kaj urinduktinfektoj. Its solution includes a multispectral optical sensor, lumfonto kaj aŭtonoma kribra aparato, kiu inkluzivas WiFi-konekton. The device scans human feces and identifies the optical footprint of fecal and urine components. It sends the data to an artificial intelligence-based cloud analysis, which then provides signs of various diseases with great precision.
OutSense develops tools to diagnose abnormalities in human feces. Informoj akiritaj de provita sango, kombinita kun plia analizo de la tempo de sangado ĝis ekskrecio, donas detalojn pri la sanganta patologio. Its specific patterns can determine whether the bleeding is from a fissure or hemorrhoid, or from a polyp, tumor or from an ulcer. In early June, OutSense anoncis tiun CommuniCare, granda sanfirmao kun pli ol 90 medical facilities in the United States, komencos piloti ĝian teknologion ĉi-jare. Krom ĉi tiu piloto, OutSense plans to conduct clinical trials in Israel and Japan.
